Abstract: An optical device including: a substrate; an optical waveguide formed at the substrate; and a protective layer formed adjacent to the optical waveguide, wherein the optical waveguide includes multiple side surfaces that intersect the substrate, at least one side surface of the optical waveguide is provided with a rough surface. According to the optical device of the present invention, the light propagation loss can be reduced.

Abstract: An all-solid-state battery comprises a power generation element and a restraint member. The restraint member applies a pressure of 0.5 MPa or less to the power generation element. The power generation element includes a positive electrode layer, a solid electrolyte layer, and a negative electrode layer. The solid electrolyte layer is interposed between the positive electrode layer and the negative electrode layer. The positive electrode layer includes a composite particle. The composite particle includes a positive electrode active material particle and a covering layer. The covering layer covers at least part of a surface of the positive electrode active material particle. The covering layer includes a sulfide solid electrolyte.

Abstract: The present invention aims to provide a novel low-molecular-weight compound showing an orexin receptor agonist activity and expected to be useful as a prophylactic or therapeutic agent for narcolepsy and the like. The present invention provides a compound represented by the formula (I): wherein each symbol is as described in the description, or a pharmaceutically acceptable acid addition salt thereof, which has an orexin receptor agonist activity, and an orexin receptor agonist containing the compound or a pharmaceutically acceptable acid addition salt thereof.

Abstract: A morphinan derivative represented by the following general formula (I): wherein R1 represents hydrogen, C1-10 alkyl, cycloalkylalkyl where the cycloalkyl moiety has 3 to 6 carbon atoms, and the alkylene moiety has 1 to 5 carbon atoms, etc.; R2 represents heterocyclic ring containing 1 to 4 heteroatoms selected from N, O and S and at least one carbon atom as ring-constituting atoms, containing at least one set of adjacent ring-constituting atoms bound by a double bond, and further substituted with at least one oxo group; Y binds to a carbon atom as a ring-constituting atom of R2; R3, R4, and R5 represent hydrogen, hydroxy, etc.; R6a and R6b represent hydrogen, etc.; R7 and R8 represent hydrogen, etc.; R9 and R10, which are the same or different, represent hydrogen, etc.; X represents O or CH2; and Y represents C(?O)); a tautomer or stereoisomer of the compound, or a pharmaceutically acceptable salt thereof, or a solvate thereof is used as an anxiolytic drug, antidepressant, etc.

Abstract: A morphinan derivative represented by the following general formula (I): wherein R1 represents hydrogen, C1-10 alkyl, cycloalkylalkyl where the cycloalkyl moiety has 3 to 6 carbon atoms, and the alkylene moiety has 1 to 5 carbon atoms, etc.; R2 represents heterocyclic ring containing 1 to 4 heteroatoms selected from N, O and S and at least one carbon atom as ring-constituting atoms, containing at least one set of adjacent ring-constituting atoms bound by a double bond, and further substituted with at least one oxo group; Y binds to a carbon atom as a ring-constituting atom of R2; R3, R4, and R5 represent hydrogen, hydroxy, etc.; R6a and R6b represent hydrogen, etc.; R7 and R8 represent hydrogen, etc.; R9 and R10, which are the same or different, represent hydrogen, etc.; X represents O or CH2; and Y represents C(?O)); a tautomer or stereoisomer of the compound, or a pharmaceutically acceptable salt thereof, or a solvate thereof is used as an anxiolytic drug, antidepressant, etc.

Abstract: A method for therapeutic treatment of pain-associated anxiety or depression in a mammalian subject in need thereof, that includes administering to the subject an effective amount of a pharmaceutical composition containing a morphinan derivative that exhibits an opioid ? receptor agonist activity.

Abstract: The present invention relates to a pharmaceutical composition comprising a morphinan derivative that exhibits an opioid ? receptor agonist activity. By administering the pharmaceutical composition provided by the present invention, opioid ? receptor-related diseases (for example, headache) can be treated or prevented.

Abstract: A main object of the present disclosure is to provide an all solid state battery with low resistance. The present disclosure achieves the object by providing an all solid state battery comprising a cathode active material layer, an anode active material layer, and a solid electrolyte layer arranged between the cathode active material layer and the anode active material layer; wherein the anode active material layer includes: a first anode active material and a second anode active material; the first anode active material is a lithium titanate; in the second anode active material, when a discharge capacity at a potential of 1.0 V vs Li+/Li or more and 2.0 V vs Li+/Li or less signifies 100% discharge capacity, and when P1 designates an average potential in a capacity of 0% or more and 50% or less of the 100% discharge capacity, and P2 designates an average potential in a capacity of 50% or more and 100% or less of the 100% discharge capacity, a difference between the P2 and the P1 is 0.

Abstract: A main object of the present disclosure is to provide an anode active material layer with low resistance. The present disclosure achieves the object by providing an anode active material layer to be used in an all solid state battery, the anode active material layer comprises: a first anode active material and a second anode active material; wherein the first anode active material is a lithium titanate; in the second anode active material, when a discharge capacity at a potential of 1.0 V vs Li+/Li or more and 2.0 V vs Li+/Li or less signifies 100% discharge capacity, and when P1 designates an average potential in a capacity of 0% or more and 50% or less of the 100% discharge capacity, and P2 designates an average potential in a capacity of 50% or more and 100% or less of the 100% discharge capacity, a difference between the P2 and the P1 is 0.

Abstract: A compound represented by the following general formula (I), wherein R1 represents hydrogen, C1-10 alkyl, cycloalkylalkyl where the cycloalkyl moiety has 3 to 6 carbon atoms and the alkylene moiety has 1 to 5 carbon atoms, or the like, R2 represents a 4- to 7-membered saturated heterocycle containing one or two heteroatoms which may be the same or different and are selected from N, O, and S, and two or more carbon atoms as ring-constituting atoms, the heterocycle may be substituted with a substituent such as an oxo group, R2 binds to Y via a carbon atom as a ring-constituting atom of R2, R3, R4, and R5, which are the same or different, represent hydrogen; hydroxy; or the like, R6a and R6b, which are the same or different, represent hydrogen or the like, R7 and R8, which are the same or different, represent hydrogen or the like, R9 and R10, which are the same or different, represent hydrogen or the like, X represents O or CH2, and Y represents C(?O) or the like), a tautomer of the compound, a stereoisome

Abstract: To provide an anode mixture configured to, when used in an all-solid-state battery, decrease the resistance of the all-solid-state battery and increase the charging performance of the all-solid-state battery, wherein the anode mixture is an anode mixture for an all-solid-state battery comprising an anode comprising an anode mixture layer; wherein the anode mixture contains a first anode active material and a second anode active material; and wherein a difference between a reaction potential of the first anode active material with respect to lithium metal and a reaction potential of the second anode active material with respect to lithium metal, is 1.0 V or more.

Abstract: A morphinan derivative represented by the following general formula (I): wherein R1 represents hydrogen, C1-10 alkyl, cycloalkylalkyl where the cycloalkyl moiety has 3 to 6 carbon atoms, and the alkylene moiety has 1 to 5 carbon atoms, etc.; R2 represents heterocyclic ring containing 1 to 4 heteroatoms selected from N, O and S and at least one carbon atom as ring-constituting atoms, containing at least one set of adjacent ring-constituting atoms bound by a double bond, and further substituted with at least one oxo group; Y binds to a carbon atom as a ring-constituting atom of R2; R3, R4, and R5 represent hydrogen, hydroxy, etc.; R6a and R6b represent hydrogen, etc.; R7 and R8 represent hydrogen, etc.; R9 and Rio, which are the same or different, represent hydrogen, etc.; X represents O or CH2; and Y represents C(?O)); a tautomer or stereoisomer of the compound, or a pharmaceutically acceptable salt thereof, or a solvate thereof is used as an anxiolytic drug, antidepressant, etc.

Abstract: The present invention aims to provide a novel low-molecular-weight compound showing an orexin receptor agonist activity and expected to be useful as a prophylactic or therapeutic agent for narcolepsy and the like. The present invention provides a compound represented by the formula (I): wherein each symbol is as described in the description, or a pharmaceutically acceptable acid addition salt thereof, which has an orexin receptor agonist activity, and an orexin receptor agonist containing the compound or a pharmaceutically acceptable acid addition salt thereof.

Abstract: A morphinan derivative represented by the following general formula (I): wherein R1 represents hydrogen, C1-10 alkyl, cycloalkylalkyl where the cycloalkyl moiety has 3 to 6 carbon atoms, and the alkylene moiety has 1 to 5 carbon atoms, etc.; R2 represents heterocyclic ring containing 1 to 4 heteroatoms selected from N, O and S and at least one carbon atom as ring-constituting atoms, containing at least one set of adjacent ring-constituting atoms bound by a double bond, and further substituted with at least one oxo group; Y binds to a carbon atom as a ring-constituting atom of R2; R3, R4, and R5 represent hydrogen, hydroxy, etc.; R6a and R6b represent hydrogen, etc.; R7 and R9 represent hydrogen, etc.; R9 and R10, which are the same or different, represent hydrogen, etc.; X represents O or CH2; and Y represents C(?O)); a tautomer or stereoisomer of the compound, or a pharmaceutically acceptable salt thereof, or a solvate thereof is used as an anxiolytic drug, antidepressant, etc.

Abstract: One aspect of the present invention provides a sulfide solid-state battery provided with: a negative electrode collector containing copper; a negative electrode mix layer disposed on the negative electrode collector, and containing a negative electrode active material; a positive electrode mix layer containing a positive electrode active material; a sulfide solid electrolyte layer sandwiched between the negative electrode mix layer and the positive electrode mix layer, and having a protruding portion that protrudes from a peripheral edge of the negative electrode mix layer and extends up to the negative electrode collector; and a reference electrode disposed in the protruding portion.

Abstract: To provide an anode mixture configured to, when used in an all-solid-state battery, decrease the resistance of the all-solid-state battery and increase the charging performance of the all-solid-state battery, wherein the anode mixture is an anode mixture for an all-solid-state battery comprising an anode comprising an anode mixture layer; wherein the anode mixture contains a first anode active material and a second anode active material; and wherein a difference between a reaction potential of the first anode active material with respect to lithium metal and a reaction potential of the second anode active material with respect to lithium metal, is 1.0 V or more.

Abstract: A morphinan derivative represented by the following general formula (I): wherein R1 represents hydrogen, C1-10 alkyl, cycloalkylalkyl where the cycloalkyl moiety has 3 to 6 carbon atoms, and the alkylene moiety has 1 to 5 carbon atoms, etc.; R2 represents heterocyclic ring containing 1 to 4 heteroatoms selected from N, O and S and at least one carbon atom as ring-constituting atoms, containing at least one set of adjacent ring-constituting atoms bound by a double bond, and further substituted with at least one oxo group; Y binds to a carbon atom as a ring-constituting atom of R2; R3, R4, and R5 represent hydrogen, hydroxy, etc.; R6a and R6b represent hydrogen, etc.; R7 and R8 represent hydrogen, etc.; R9 and Rio, which are the same or different, represent hydrogen, etc.; X represents O or CH2; and Y represents C(?O)); a tautomer or stereoisomer of the compound, or a pharmaceutically acceptable salt thereof, or a solvate thereof is used as an anxiolytic drug, antidepressant, etc.

Abstract: The present invention relates to a nalfurafine-containing percutaneous absorption patch having a support, a drug layer and a control layer which are laminated successively, wherein the drug layer contains at least one kind of a drug selected from the group consisting of nalfurafine and a salt thereof, and capable of maintaining a given level of drug skin permeation amount without permeation of an excess amount of the drug through the skin in a short time even when applied to the skin in which the horny cell layer and the like are damaged and the skin barrier is insufficient.

Abstract: The present invention relates to a pharmaceutical composition comprising a morphinan derivative that exhibits an opioid ? receptor agonist activity. By administering the pharmaceutical composition provided by the present invention, opioid ? receptor related diseases (for example, headache) can be treated or prevented.

Abstract: One aspect of the present invention provides a sulfide solid-state battery provided with: a negative electrode collector containing copper; a negative electrode mix layer disposed on the negative electrode collector, and containing a negative electrode active material; a positive electrode mix layer containing a positive electrode active material; a sulfide solid electrolyte layer sandwiched between the negative electrode mix layer and the positive electrode mix layer, and having a protruding portion that protrudes from a peripheral edge of the negative electrode mix layer and extends up to the negative electrode collector; and a reference electrode disposed in the protruding portion.